395 related articles for article (PubMed ID: 27530326)
1. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
3. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
[TBL] [Abstract][Full Text] [Related]
4. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
6. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
7. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
9. Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of
Teng K; Ford MJ; Harwalkar K; Li Y; Pacis AS; Farnell D; Yamanaka N; Wang YC; Badescu D; Ton Nu TN; Ragoussis J; Huntsman DG; Arseneau J; Yamanaka Y
Cancer Res; 2021 Oct; 81(20):5147-5160. PubMed ID: 34301761
[TBL] [Abstract][Full Text] [Related]
10. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract][Full Text] [Related]
11. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
12. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
13. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract][Full Text] [Related]
14. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.
Iyer S; Zhang S; Yucel S; Horn H; Smith SG; Reinhardt F; Hoefsmit E; Assatova B; Casado J; Meinsohn MC; Barrasa MI; Bell GW; Pérez-Villatoro F; Huhtinen K; Hynninen J; Oikkonen J; Galhenage PM; Pathania S; Hammond PT; Neel BG; Farkkila A; Pépin D; Weinberg RA
Cancer Discov; 2021 Feb; 11(2):384-407. PubMed ID: 33158843
[TBL] [Abstract][Full Text] [Related]
15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
16. Concurrent RB1 loss and
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Blake Gilks C; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; ; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Rinda Soong T; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
medRxiv; 2023 Nov; ():. PubMed ID: 37986741
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
18. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
[TBL] [Abstract][Full Text] [Related]
20. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
